Related Experiment Video
Updated: Jan 16, 2026
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
18.6K
Effectiveness of Statins for Oxaliplatin-Induced Peripheral Neuropathy: A Multicenter Retrospective Observational
Kenshi Takechi1, Takehiro Kawashiri2, Keisuke Mine2
1Department of Drug Information Analysis, College of Pharmaceutical Sciences, Matsuyama University, Matsuyama, Japan.
Clinical and Translational Science
|September 29, 2025
Summary
Statins may protect against oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer patients. This study found no overall OIPN protection but a significant benefit in CRC patients using statins.
Area of Science:
- Oncology
- Neurology
- Pharmacology
Background:
- Oxaliplatin-induced peripheral neuropathy (OIPN) significantly impacts patient quality of life.
- Statins, known for cholesterol-lowering, possess pleiotropic effects, including potential neuroprotection.
- Large-scale real-world data on statin efficacy against OIPN is lacking.
Purpose of the Study:
- To investigate the protective effect of statins against OIPN in a real-world clinical setting.
- To assess the association between statin use and OIPN incidence in cancer patients receiving oxaliplatin.
Main Methods:
- A multicentre retrospective study of Japanese patients receiving oxaliplatin-based chemotherapy (April 2009 - December 2019).
- Propensity score matching was employed to compare OIPN incidence between statin and non-statin users.
- Analysis included overall cancer patients and a subgroup of colorectal cancer (CRC) patients.
Main Results:
- Overall, 24.7% of 2657 patients developed Grade ≥2 OIPN, with no significant difference between statin and non-statin groups post-matching.
- In matched CRC patients (n=510), statin use was associated with a significantly lower incidence of Grade ≥2 OIPN (19.8% vs. 28.3%, p=0.029).
Conclusions:
- Statins do not appear to offer significant protection against OIPN in the general cancer patient population treated with oxaliplatin.
- Evidence suggests statins may provide a neuroprotective benefit specifically for colorectal cancer patients experiencing OIPN.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:26Peripheral Artery Disease IV: Nursing Management
350
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
350
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
197
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
197
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
256
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
256
01:27Peripheral Artery Disease III: Interprofessional Care
245
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
245